Upfront, milestones and royalty payments from Pfizer Inc., the newly recruited European licensee for Basilea Pharmaceutica Ltd.’s antifungal, Cresemba (isavuconazole), should give a welcome boost to the Swiss company’s strategy of developing early clinical-stage products to overcome resistance to anti-infective and oncology medicines, and finding additional partners around the world for its marketed products that include Cresemba and the antibiotic, Zevtera/Mabelio (ceftobiprole).
Basilea has spent the past year or so making Cresemba available in key European markets, including Germany, Italy, the UK,...








